Document:

EX-10.1

 Exhibit 10.1 
 VERISK ANALYTICS, INC. 
 DIRECTOR COMPENSATION PROGRAM 

(Effective 2012) 
 Annual compensation for members of the Board of Directors of the Verisk Analytics, Inc. (the “Company”) shall be as follows: 
 I. EMPLOYEE DIRECTORS: 
 Directors who are also employees of the Company
shall receive no additional compensation for their service as Directors. 
 II. NON-EMPLOYEE DIRECTORS: 

A. Retainers: 
 Annual
Retainer. Each non-employee Director shall be entitled to an annual retainer fee of $75,000. Such fee shall be payable in July of each year; provided however, that for 2012 such amount, minus any annual retainer fee amount paid in July 2012, shall
be payable upon adoption of this plan by the Compensation Committee. 
 Chairperson’s Retainer. The Chairperson of the Audit Committee of
the Board of Directors of the Company (who shall not be an employee of the Company) shall be entitled to an additional annual retainer fee of $15,000. The Chairperson of the Compensation Committee of the Board of Directors of the Company (who shall
not be an employee of the Company) shall be entitled to an additional annual retainer fee of $15,000. Each non-employee Director who chairs any other Committee shall be entitled to an additional annual retainer fee of $10,000. Such fees shall be
payable in July of each year; provided however, that for 2012 such amount, minus any Chairperson’s Retainer fee amount paid in July 2012, shall be payable upon adoption of this plan by the Compensation Committee. 

Presiding Director Retainer. The Presiding Director (who shall not be an employee of the Company) shall be entitled to an additional annual retainer fee
of $15,000. Such fee shall be payable in July of each year; provided however, that for 2012 such fee shall be payable upon adoption of this plan by the Compensation Committee. 
 Manner of Payment: Any retainer amounts payable pursuant to this Section II. A. may be taken in the form of (i) cash, (ii) Class A Common Stock of the Company, or (ii) options to
purchase Class A Common Stock of the Company (or any combination thereof as the Director may elect). 
 Deferral Election. A Director may
defer receipt of any portion of such retainer amount to be received in the form of (i) cash or (ii) Class A Common Stock. Any such deferral election must be made in writing and delivered to the Secretary of the Company no later than
December 31 of the year prior to the year in which such amount shall be payable. For example, an election to defer receipt of cash or Common Stock retainer amounts payable in July 2013 must be made no later than December 31, 2012. Cash or
shares the receipt of which are deferred pursuant to any such election will be distributed to Directors upon retirement or other separation from the Board of Directors. 
 B. Annual Equity Award: 
 Annual Grant. Each non-employee Director shall be entitled to an
annual equity award having a value of $125,000. Such awards shall be made effective as of July 1 each calendar year. One-half of such value shall awarded in the form of options to purchase Class A Common Stock (based on the Black-Scholes
value on the date of grant) and one-half of such value shall be awarded in the form of deferred stock units (based on the value of a share of Class A Common Stock on the date of grant). Class A Common Stock in respect of deferred stock
units will be distributed to Directors upon retirement or other separation from the Board of Directors. 
 The Compensation Committee shall
periodically review the provisions of this policy, and recommend modifications as the Committee shall deem appropriate.EX-10.1

 Exhibit 10.1 
 FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
 THIS
FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (“Amendment”) is entered into as of August 20, 2012, by and among CryoLife, Inc., a Florida corporation (“CryoLife”), AuraZyme Pharmaceuticals, Inc., a
Florida corporation (“AuraZyme”), CryoLife International, Inc., a Florida corporation (“International”), Cardiogenesis Corporation, a Florida corporation (“Cardiogenesis”) (CryoLife, AuraZyme,
International and Cardiogenesis are sometimes referred to herein together as the “Borrowers” and individually as a “Borrower”), CryoLife, as Borrower Representative, the other Credit Parties party hereto, General
Electric Capital Corporation, a Delaware corporation (the “Agent”), as administrative agent for the lenders from time to time party to the Credit Agreement described below (collectively, the “Lenders” and
individually each a “Lender”) and for itself as a Lender and L/C Issuer, and such Lenders. 
 RECITALS

 A. The Borrowers, the other Credit Parties signatory thereto, the Lenders signatory thereto from time to time and Agent
are parties to that certain Amended and Restated Credit Agreement, dated as of October 28, 2011 (as amended, supplemented, revised, restated, replaced or otherwise modified, the “Credit Agreement”). Capitalized terms used in
this Amendment without definition shall have the meanings ascribed to such terms in the Credit Agreement, as applicable. 
 B.
The Borrowers have requested that Lenders amend the Credit Agreement in certain respects and Lenders have agreed to so amend the Credit Agreement, subject to the terms and conditions hereof. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereinafter contained, and intending to be legally bound, the
parties hereto agree as follows: 
 A. AMENDMENTS 

1. Amendment to Section 5.11 Section 5.11 of the Credit Agreement is amended by deleting the word “and” at the
end of clause (c)(iv) thereto, replacing the “.” at the end of clause (d) thereto with “; and”, and adding the following new clause (e) thereto: 

(e) CryoLife may declare and make dividend payments with respect to its common stock in an aggregate amount not to exceed
$3,000,000 in any fiscal year; provided, that, both before and after giving pro forma effect to each such dividend payment and any Loan made on the date such dividend payment is made, (i) the Credit Parties shall be in compliance
on a pro forma basis with the covenants set forth in Article VI as of the most recently ended fiscal quarter for which financial statements have been delivered under Section 4.1(a) or (c), (ii) the Leverage Ratio
calculated as of the date of such dividend payment (except with respect to Adjusted EBITDA which shall be calculated as of the most recently 

 
ended twelve month period for which financial statements have been delivered under Section 4.1(b)) shall be less than 1.00:1.00, and (iii) no Default or Event of Default shall
have occurred and be continuing. 
 B. CONDITIONS TO EFFECTIVENESS 

Notwithstanding any other provision of this Amendment and without affecting in any manner the rights of the Lenders hereunder, it is
understood and agreed that this Amendment shall not become effective, and the Borrower shall have no rights under this Amendment, until Agent shall have received (a) duly executed signature pages to this Amendment from the Lenders, Borrowers,
L/C Issuer, Agent and each Credit Party, and (b) an amendment fee in the amount of $25,000. 
 C. REPRESENTATIONS

 Each Credit Party hereby represents and warrants to Lenders, L/C Issuer and Agent that: 

1. The execution, delivery and performance by such Credit Party of this Amendment (a) are within such Credit Party’s power;
(b) have been duly authorized by all necessary corporate, limited liability company or limited partnership action; (c) are not in contravention of any provision of such Credit Party’s certificate of incorporation or bylaws or other
organizational documents; (d) do not violate any law or regulation, or any order or decree of any Governmental Authority; (e) do not conflict with or result in the breach or termination of, constitute a default under or accelerate any
performance required by, any indenture, mortgage, deed of trust, lease, agreement or other instrument to which such Credit Party or any of its Subsidiaries is a party or by which such Credit Party or any such Subsidiary or any of their respective
property is bound; (f) do not result in the creation or imposition of any Lien upon any of the property of such Credit Party or any of its Subsidiaries other than those in favor of Agent, on behalf of itself and the Lenders, pursuant to the
Loan Documents; and (g) do not require the consent or approval of any Governmental Authority or any other Person. 
 2.
This Amendment has been duly executed and delivered for the benefit of or on behalf of each Credit Party and constitutes a legal, valid and binding obligation of each Credit Party, enforceable against such Credit Party in accordance with its terms
except as the enforceability hereof may be limited by bankruptcy, insolvency, reorganization, moratorium and other laws affecting creditors’ rights and remedies in general. 

3. Both before and after giving effect to this Amendment, the representations and warranties contained in the Credit Agreement and the
other Loan Documents are true and correct in all material respects and no Default or Event of Default has occurred and is continuing as of the date hereof. 
 D. OTHER AGREEMENTS 
 1. Continuing Effectiveness of Loan Documents.
As amended hereby, all terms of the Credit Agreement and the other Loan Documents shall be and remain in full force 

  
 2 

 
and effect and shall constitute the legal, valid, binding and enforceable obligations of the Credit Parties party thereto. To the extent any terms and conditions in any of the other Loan
Documents shall contradict or be in conflict with any terms or conditions of the Credit Agreement, after giving effect to this Amendment, such terms and conditions are hereby deemed modified and amended accordingly to reflect the terms and
conditions of the Credit Agreement as modified and amended hereby. Upon the effectiveness of this Amendment such terms and conditions are hereby deemed modified and amended accordingly to reflect the terms and conditions of the Credit Agreement as
modified and amended hereby. 
 2. Reaffirmation of Loan Documents. Each Credit Party consents to the execution and
delivery of this Amendment by all parties hereto and the consummation of the transactions described herein, and ratifies and confirms the terms of the Credit Agreement, that certain Guaranty and Security Agreement, dated as of March 27, 2008
and reaffirmed by that certain Omnibus Reaffirmation Agreement, dated as of October 28, 2011 (as amended, supplemented, modified, the “Guaranty and Security Agreement”) and each other Loan Document to which such Credit Party is
a party with respect to the indebtedness now or hereafter outstanding under the Credit Agreement as amended hereby and all promissory notes issued thereunder. Each Credit Party acknowledges that, notwithstanding anything to the contrary contained
herein or in any other document evidencing any indebtedness of any Borrower to the Lenders or any other obligation of Borrowers, or any actions now or hereafter taken by the Lenders with respect to any obligation of Borrowers, the Guaranty and
Security Agreement (i) is and shall continue to be a primary obligation of such Credit Party, (ii) is and shall continue to be an absolute, unconditional, continuing and irrevocable guaranty of payment, and (iii) is and shall continue
to be in full force and effect in accordance with its terms. Nothing contained herein to the contrary shall release, discharge, modify, change or affect the original liability of any Credit Party under the Guaranty and Security Agreement.

 3. Acknowledgment of Perfection of Security Interest. Each Credit Party hereby acknowledges that, as of the date
hereof, the security interests and liens granted to Agent, the L/C Issuer and the Lenders under the Credit Agreement and the other Loan Documents are in full force and effect, are properly perfected and are enforceable in accordance with the terms
of the Credit Agreement and the other Loan Documents. 
 4. Effect of Agreement. Except as set forth expressly herein,
all terms of the Credit Agreement, as amended hereby, and the other Loan Documents shall be and remain in full force and effect and shall constitute the legal, valid, binding and enforceable obligations of the Borrowers to the Lenders, the L/C
Issuer and Agent. The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Lenders under the Credit Agreement, nor constitute a waiver of any
provision of the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement. 

5. Governing Law. This Amendment shall be governed by, and construed in accordance with, the internal laws of the State of
New York and all applicable federal laws of the United States of America. 

  
 3 

 6. No Novation. This Amendment is not intended by the parties to be, and shall
not be construed to be, a novation of the Credit Agreement and the other Loan Documents or an accord and satisfaction in regard thereto. 
 7. Costs and Expenses. The Borrowers agree to pay on demand all costs and expenses of Agent in connection with the preparation, execution and delivery of this Amendment, including, without
limitation, the reasonable fees and out-of-pocket expenses of outside counsel for Agent with respect thereto. 
 8.
Counterparts. This Amendment may be executed by one or more of the parties hereto in any number of separate counterparts, each of which shall be deemed an original and all of which, taken together, shall be deemed to constitute one and the
same instrument. Delivery of an executed counterpart of this Amendment by facsimile transmission, Electronic Transmission or containing an E-Signature shall be as effective as delivery of a manually executed counterpart hereof. 

9. Binding Nature. This Amendment shall be binding upon and inure to the benefit of the parties hereto, their respective
successors, successors-in-titles, and assigns. 
 10. Entire Understanding. This Amendment sets forth the entire
understanding of the parties with respect to the matters set forth herein, and shall supersede any prior negotiations or agreements, whether written or oral, with respect thereto. 

[signature pages to follow] 

  
 4 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the date first written
above. 
  

			
	BORROWERS:
	
	CRYOLIFE, INC.
		
	By:	 	 /s/ D.A. Lee

	Title:	 	EVP, COO and CFO
	
	AURAZYME PHARMACEUTICALS, INC.
		
	By:	 	 /s/ D.A. Lee

	Title:	 	VP, Finance, CFO and Treasurer
	
	CRYOLIFE INTERNATIONAL, INC.
		
	By:	 	 /s/ D.A. Lee

	Title:	 	VP, CFO and Treasurer
	
	CARDIOGENESIS CORPORATION
		
	By:	 	 /s/ D.A. Lee

	Title:	 	EVP, COO and CFO
	
	AGENT, L/C ISSUER AND LENDERS:
	
	GENERAL ELECTRIC CAPITAL
	CORPORATION, as Agent, L/C Issuer and sole Lender
		
	By:	 	 /s/ Andrew Moore

		 	Its Duly Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]